Aim of this study is to evaluate if migraine, daily chronic headache and fibromyalgia in the same patient can be considered as an evolutive continuum of non organic chronic pain. Therefore, migraine, daily chronic headache and fibromyalgia should be considered the expression of chronic antinociceptive system alteration.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10072-004-0314-4 | DOI Listing |
Headache
January 2025
Department of Neurological Surgery, Rutgers-New Jersey Medical School, Newark, New Jersey, USA.
A patient with persistent refractory headaches from aneurysmal subarachnoid hemorrhage was treated with monthly erenumab injections, a monoclonal antibody to the calcitonin gene-related peptide (CGRP) receptor. These injections decreased the frequency and severity of the patient's debilitating headaches from daily to once or twice per month with positive improvement in function and quality of life. To our knowledge, this is the first reported case in the literature of a patient with persistent post-subarachnoid hemorrhage headache that was successfully treated with an antibody against the CGRP receptor.
View Article and Find Full Text PDFFront Neurol
January 2025
Department of Neurology, Ibn Sina Hospital, Safat, Kuwait.
Background: OnabotulinumtoxinA (BoNT-A) is approved as a prophylactic treatment of chronic migraine (CM) only. We aimed to assess the efficacy and safety of BoNT-A in the treatment of episodic migraine (EM).
Methods: This is a prospective study included migraine patients, aged 18-65 years, and completed 1 year treatment with BoNT-A.
J Clin Neurosci
January 2025
Family and Community Medicine Department, College of Medicine, King Khalid University, Abha, Saudi Arabia.
Background: Migraine is a common primary headache disorder that significantly affects academic life and is often associated with stress, depression, anxiety, and irregular sleep patterns among university students. This study aimed to assess the prevalence of migraine among King Khalid University (KKU) students, identify its determinants, and evaluate the impact of migraine and other headaches on academic life and performance.
Methods: An analytical cross-sectional study was conducted among 732 students from Colleges of Medicine, Pharmacy, Engineering, and Computer science.
Headache
January 2025
Service of Neurology, University Hospital Marqués de Valdecilla, Universidad de Cantabria and Valdecilla Research Institute (IDIVAL), Santander, Spain.
Background: Serum 25-hydroxyvitamin D (25[OH]D) concentrations have been shown to be low in patients with migraine, but results are controversial regarding the current role of vitamin D in migraine severity. Using a case-control design, we aimed to evaluate serum 25(OH)D levels in a group of females with high-frequency episodic migraine/chronic migraine (HF/CM) and analyze its association with headache frequency and serum calcitonin gene-related peptide (CGRP) levels.
Methods: Serum 25(OH)D levels were measured in 97 females with HF/CM (age 48.
Pain Manag Nurs
January 2025
Headache Unit, Neurology Service, Vall d'Hebron University Hospital, Barcelona, Spain; Headache Research Group, Vall d'Hebron Research Institute, Autònoma University of Barcelona, Barcelona, Spain. Electronic address:
Purpose: Headache is a prevalent and highly disabling neurological disorder. There are no data on its prevalence in and impact on hospitalized patients. The objective of this study was to describe the prevalence of headache in hospitalized patients, triggers associated with headaches in this population, and compliance with documentation in the electronic medical record system (EMRS).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!